Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis.

Vuilleumier N, Bas S, Pagano S, Montecucco F, Guerne PA, Finckh A, Lovis C, Mach F, Hochstrasser D, Roux-Lombard P, Gabay C.

Arthritis Rheum. 2010 Sep;62(9):2640-50. doi: 10.1002/art.27546.

2.

Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.

Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, Burkhard PR, Mensi N, Righini M, Reber G, James R, Mach F, Chevrolet JC, Dayer JM, Frostegard J, Roux-Lombard P.

Clin Sci (Lond). 2008 Jul;115(1):25-33.

PMID:
18088236
3.

Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?

Finckh A, Courvoisier DS, Pagano S, Bas S, Chevallier-Ruggeri P, Hochstrasser D, Roux-Lombard P, Gabay C, Vuilleumier N.

Arthritis Care Res (Hoboken). 2012 Jun;64(6):817-25. doi: 10.1002/acr.21631. Epub 2012 Feb 2.

4.

Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy.

Vuilleumier N, Montecucco F, Spinella G, Pagano S, Bertolotto M, Pane B, Pende A, Galan K, Roux-Lombard P, Combescure C, Dallegri F, Mach F, Palombo D.

Thromb Haemost. 2013 Apr;109(4):706-15. doi: 10.1160/TH12-10-0714. Epub 2013 Jan 31.

PMID:
23364307
5.

Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus.

O'Neill SG, Giles I, Lambrianides A, Manson J, D'Cruz D, Schrieber L, March LM, Latchman DS, Isenberg DA, Rahman A.

Arthritis Rheum. 2010 Mar;62(3):845-54. doi: 10.1002/art.27286.

6.

Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity.

Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafström I, Frostegård J.

Scand J Rheumatol. 2010 Nov;39(6):447-53. doi: 10.3109/03009741003742755. Epub 2010 Jul 6.

PMID:
20604674
7.

Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis.

Wick PA, Mombelli A, Pagano S, Moren X, Giannopoulou C, Mach F, Roux-Lombard P, Vuilleumier N.

J Periodontal Res. 2013 Jun;48(3):350-6. doi: 10.1111/jre.12014. Epub 2012 Oct 11.

PMID:
23050768
8.

Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction.

Vuilleumier N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, James R, Reber G, Mach F, Roux-Lombard P.

Eur Heart J. 2010 Apr;31(7):815-23. doi: 10.1093/eurheartj/ehq055. Epub 2010 Feb 22.

PMID:
20176799
9.

Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.

Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB.

J Lipid Res. 2007 Feb;48(2):425-33. Epub 2006 Nov 8.

10.

Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability.

Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V, Pelli G, Kovari E, Pane B, Spinella G, Pende A, Palombo D, Dallegri F, Mach F, Roux-Lombard P.

Eur Heart J. 2011 Feb;32(4):412-21. doi: 10.1093/eurheartj/ehq521. Epub 2011 Jan 11.

PMID:
21224292
11.
12.

High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.

Santos AO, Fonseca FA, Fischer SM, Monteiro CM, Brandão SA, Póvoa RM, Bombig MT, Carvalho AC, Monteiro AM, Ramos E, Gidlund M, Figueiredo Neto AM, Izar MC.

Clin Chim Acta. 2009 Aug;406(1-2):113-8. doi: 10.1016/j.cca.2009.06.005. Epub 2009 Jun 10.

PMID:
19523463
13.

IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.

Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, Lee SS, Joo YS, Min JK, Hong YS, Lee SH, Park SH, Cho CS, Kim HY.

J Rheumatol. 2000 Mar;27(3):575-81.

PMID:
10743792
14.

High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage.

Pruijm M, Schmidtko J, Aho A, Pagano S, Roux-Lombard P, Teta D, Burnier M, Vuilleumier N.

Ther Apher Dial. 2012 Dec;16(6):588-94. doi: 10.1111/j.1744-9987.2012.01102.x. Epub 2012 Sep 12.

PMID:
23190520
15.

Interleukin-18: an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow-up.

Furtado MV, Rossini AP, Campani RB, Meotti C, Segatto M, Vietta G, Polanczyk CA.

Coron Artery Dis. 2009 Aug;20(5):327-331.

PMID:
19593889
16.

Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.

Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, Sugii S, Ozawa Y, Tohma S.

J Rheumatol. 2006 Dec;33(12):2390-7. Epub 2006 Aug 15.

PMID:
16924694
17.

Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex.

Pagano S, Satta N, Werling D, Offord V, de Moerloose P, Charbonney E, Hochstrasser D, Roux-Lombard P, Vuilleumier N.

J Intern Med. 2012 Oct;272(4):344-57. doi: 10.1111/j.1365-2796.2012.02530.x. Epub 2012 Mar 26.

20.

[Anti-lipoprotein autoantibodies with hypolipidemia in infectious rheumatism].

Noseda G.

Schweiz Med Wochenschr. 1975;105(31 Suppl):1-58. German.

PMID:
168637

Supplemental Content

Support Center